{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:50:37Z","timestamp":1790790637835,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A substantial minority of early breast cancer (EBC) patients relapse despite their tumors achieving pathologic complete response (pCR) after neoadjuvant therapy. We compared gene expression (BC360; nCounter<jats:sup>\u00ae<\/jats:sup> platform; NanoString) between primary tumors of patients with post-pCR relapse (<jats:italic>N<\/jats:italic>\u2009=\u200914) with: (i) matched recurrent tumors from same patient (intraindividual analysis); and (ii) primary tumors from matched controls with pCR and no relapse (<jats:italic>N<\/jats:italic>\u2009=\u200941; interindividual analysis). Intraindividual analysis showed lower estrogen receptor signaling signature expression in recurrent tumors versus primaries (logFC = \u22120.595; <jats:italic>P<\/jats:italic>\u2009=\u20090.022). Recurrent tumors in patients with distant metastases also exhibited reduced expression of immune-related expression parameters. In interindividual analyses, primary tumor major histocompatibility complex class II expression was lower versus controls in patients with any relapse (logFC = \u22120.819; <jats:italic>P<\/jats:italic>\u2009=\u20090.030) or distant relapse (logFC = \u22121.151; <jats:italic>P<\/jats:italic>\u2009=\u20090.013). Primaries with later distant relapse also had greater homologous recombination deficiency than controls (logFC = 0.649; <jats:italic>P<\/jats:italic>\u2009=\u20090.026). Although no associations remained statistically significant following adjustment for false discovery rate, our results show that transcriptomic analyses have potential for prognostic value and may help in selecting optimal treatment regimens for EBC at risk of relapse and warrant further investigation.<\/jats:p>","DOI":"10.1038\/s41523-022-00403-3","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T10:17:07Z","timestamp":1648549027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Gene signatures in patients with early breast cancer and relapse despite pathologic complete response"],"prefix":"10.1038","volume":"8","author":[{"given":"Simona","family":"Bruzas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Gluz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Seiberling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6466-4717","authenticated-orcid":false,"given":"Ouafaa","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakima","family":"Harrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-0803","authenticated-orcid":false,"given":"Satyendra","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Dyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Traut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Theuerkauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherko","family":"Kuemmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-8595","authenticated-orcid":false,"given":"Mattea","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"403_CR1","doi-asserted-by":"publisher","unstructured":"Cardoso, F. et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz173 (2019).","DOI":"10.1093\/annonc\/mdz173"},{"key":"403_CR2","doi-asserted-by":"publisher","unstructured":"Hayes, D. F. & Schott, A. F. Neoadjuvant chemotherapy: What are the benefits for the patient and for the investigator? J. Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jncimonographs\/lgv004 (2015).","DOI":"10.1093\/jncimonographs\/lgv004"},{"key":"403_CR3","doi-asserted-by":"publisher","unstructured":"Mamtani, A. et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann. Surg. Oncol. https:\/\/doi.org\/10.1245\/s10434-016-5246-8 (2016).","DOI":"10.1245\/s10434-016-5246-8"},{"key":"403_CR4","doi-asserted-by":"publisher","unstructured":"Colomer, R. et al. Neoadjuvant management of early breast cancer: a clinical and investigational position statement. Oncologist https:\/\/doi.org\/10.1634\/theoncologist.2018-0228 (2019).","DOI":"10.1634\/theoncologist.2018-0228"},{"key":"403_CR5","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring, L. M. et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin. Cancer Res. 26, 2838\u20132848 (2020).","journal-title":"Clin. Cancer Res."},{"key":"403_CR6","doi-asserted-by":"publisher","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8 (2014).","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"403_CR7","doi-asserted-by":"publisher","unstructured":"Chica-Parrado, M. R. et al. Resistance to neoadjuvant treatment in breast cancer: clinicopathological and molecular predictors. Cancers https:\/\/doi.org\/10.3390\/cancers12082012 (2020).","DOI":"10.3390\/cancers12082012"},{"key":"403_CR8","doi-asserted-by":"publisher","unstructured":"Masuda, N. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1612645 (2017).","DOI":"10.1056\/NEJMoa1612645"},{"key":"403_CR9","doi-asserted-by":"publisher","unstructured":"Von Minckwitz, G. et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1814017 (2019).","DOI":"10.1056\/NEJMoa1814017"},{"key":"403_CR10","doi-asserted-by":"publisher","unstructured":"Tanioka, M. et al. Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br. J. Cancer https:\/\/doi.org\/10.1038\/sj.bjc.6605769 (2010).","DOI":"10.1038\/sj.bjc.6605769"},{"key":"403_CR11","doi-asserted-by":"crossref","unstructured":"Huober, J. et al. Abstract P2-08-01: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy\u2014results of a pooled analysis based on the GBG meta-database. Cancer Res. 79 P2-08-01\u2013P2-08\u201301 (2019).","DOI":"10.1158\/1538-7445.SABCS18-P2-08-01"},{"key":"403_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-015-3533-x","volume":"153","author":"M Chaudry","year":"2015","unstructured":"Chaudry, M. et al. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 153, 417\u2013423 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"403_CR13","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.ejso.2019.08.001","volume":"45","author":"M Asaoka","year":"2019","unstructured":"Asaoka, M. et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. Eur. J. Surg. Oncol. 45, 2289\u20132294 (2019).","journal-title":"Eur. J. Surg. Oncol."},{"key":"403_CR14","doi-asserted-by":"publisher","unstructured":"Weiss, A., Bashour, S. I., Hess, K., Thompson, A. M. & Ibrahim, N. K. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Res. https:\/\/doi.org\/10.1186\/s13058-018-0945-7 (2018).","DOI":"10.1186\/s13058-018-0945-7"},{"key":"403_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40\u201350 (2018).","journal-title":"Lancet Oncol."},{"key":"403_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/1078-0432.CCR-15-0630","volume":"22","author":"A Prat","year":"2016","unstructured":"Prat, A. et al. Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay. Clin. Cancer Res. 22, 560\u2013566 (2016).","journal-title":"Clin. Cancer Res."},{"key":"403_CR17","doi-asserted-by":"publisher","unstructured":"Callari, M. et al. Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0757 (2016).","DOI":"10.1158\/1078-0432.CCR-15-0757"},{"key":"403_CR18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10549-011-1895-2","volume":"132","author":"LJ Esserman","year":"2012","unstructured":"Esserman, L. J. et al. Chemotherapy response and recurrence-free survival in Neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657). Breast Cancer Res. Treat. 132, 1049\u20131062 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"403_CR19","first-page":"2555","volume":"10","author":"T Takeshita","year":"2020","unstructured":"Takeshita, T. et al. Transcriptomic and functional pathway features were associated with survival after pathological complete response to neoadjuvant chemotherapy in breast cancer. Am. J. Cancer Res. 10, 2555\u20132569 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"403_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000507055","volume":"87","author":"L Annaratone","year":"2020","unstructured":"Annaratone, L. et al. The multifaceted nature of tumor microenvironment in breast carcinomas. Pathobiology 87, 125\u2013142 (2020).","journal-title":"Pathobiology"},{"key":"403_CR21","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1200\/JCO.2019.37.15_suppl.2631","volume":"37","author":"JD Wulfkuhle","year":"2019","unstructured":"Wulfkuhle, J. D. et al. Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial. J. Clin. Oncol. 37, 2631\u20132631 (2019).","journal-title":"J. Clin. Oncol."},{"key":"403_CR22","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/intimm\/dxl092","volume":"18","author":"SA Oldford","year":"2006","unstructured":"Oldford, S. A. et al. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int. Immunol. 18, 1591\u20131602 (2006).","journal-title":"Int. Immunol."},{"key":"403_CR23","doi-asserted-by":"publisher","unstructured":"Andres, F. et al. Expression of the MHC class II pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes. Cancer Immunol. Res. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0243 (2016).","DOI":"10.1158\/2326-6066.CIR-15-0243"},{"key":"403_CR24","doi-asserted-by":"publisher","unstructured":"Park, I. A. et al. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0182786 (2017).","DOI":"10.1371\/journal.pone.0182786"},{"key":"403_CR25","doi-asserted-by":"publisher","unstructured":"Stewart, R. L. et al. A multigene assay determines risk of recurrence in patients with triple-negative breast cancer. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3014 (2019).","DOI":"10.1158\/0008-5472.CAN-18-3014"},{"key":"403_CR26","doi-asserted-by":"publisher","unstructured":"Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4+ T cells in cancer immunotherapy\u2014new insights into old paradigms. Cancer Gene Therapy https:\/\/doi.org\/10.1038\/s41417-020-0183-x (2020).","DOI":"10.1038\/s41417-020-0183-x"},{"key":"403_CR27","doi-asserted-by":"publisher","unstructured":"Blomberg, O. S., Spagnuolo, L. & De Visser, K. E. Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. DMM Disease Models and Mechanisms (2018) https:\/\/doi.org\/10.1242\/dmm.036236.","DOI":"10.1242\/dmm.036236"},{"key":"403_CR28","doi-asserted-by":"publisher","unstructured":"Axelrod, M. L., Cook, R. S., Johnson, D. B. & Balko, J. M. Biological consequences of MHC-II expression by tumor cells in cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3200 (2019).","DOI":"10.1158\/1078-0432.CCR-18-3200"},{"key":"403_CR29","doi-asserted-by":"publisher","unstructured":"Loi, S. et al. RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1125 (2016).","DOI":"10.1158\/1078-0432.CCR-15-1125"},{"key":"403_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi, L., Rugo, H. S. & Jackisch, C. An overview of PARP inhibitors for the treatment of breast cancer. Target. Oncol. 16, 255\u2013282 (2021).","journal-title":"Target. Oncol."},{"key":"403_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s13058-014-0475-x","volume":"16","author":"KM Timms","year":"2014","unstructured":"Timms, K. M. et al. Association of BRCA1\/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 16, 475 (2014).","journal-title":"Breast Cancer Res"},{"key":"403_CR32","doi-asserted-by":"crossref","unstructured":"Force, J. et al. Abstract P3-08-07: distinct biological signatures describe differences in BRCA mutated subgroups. Cancer Res. 79, P3-08\u201307 (2019).","DOI":"10.1158\/1538-7445.SABCS18-P3-08-07"},{"key":"403_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10549-017-4624-7","volume":"168","author":"T ML","year":"2018","unstructured":"ML, T. et al. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1\/2 mutation-associated breast cancer. Breast Cancer Res. Treat. 168, 625\u2013630 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"403_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.annonc.2020.12.016","volume":"32","author":"D C","year":"2021","unstructured":"C, D. et al. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy \u22c6. Ann. Oncol. 32, 500\u2013511 (2021).","journal-title":"Ann. Oncol."},{"key":"403_CR35","doi-asserted-by":"publisher","unstructured":"Mohammed, R. A. A. et al. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod. Pathol. https:\/\/doi.org\/10.1038\/modpathol.2011.4 (2011).","DOI":"10.1038\/modpathol.2011.4"},{"key":"403_CR36","doi-asserted-by":"publisher","unstructured":"Uzzan, B., Nicolas, P., Cucherat, M. & Perret, G. Y. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-1957 (2004).","DOI":"10.1158\/0008-5472.CAN-03-1957"},{"key":"403_CR37","doi-asserted-by":"publisher","unstructured":"Giatromanolaki, A., Sivridis, E., Fiska, A. & Koukourakis, M. I. The CD44+\/CD24- phenotype relates to \u2018triple-negative\u2019 state and unfavorable prognosis in breast cancer patients. Med. Oncol. https:\/\/doi.org\/10.1007\/s12032-010-9530-3 (2011).","DOI":"10.1007\/s12032-010-9530-3"},{"key":"403_CR38","doi-asserted-by":"publisher","unstructured":"Gooding, A. J. & Schiemann, W. P. Epithelial\u2013mesenchymal transition programs and cancer stem cell phenotypes: mediators of breast cancer therapy resistance. Mol. Cancer Res. https:\/\/doi.org\/10.1158\/1541-7786.mcr-20-0067 (2020).","DOI":"10.1158\/1541-7786.mcr-20-0067"},{"key":"403_CR39","doi-asserted-by":"publisher","unstructured":"Denkert, C. et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant gepartrio trial. Ann. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdt350 (2013).","DOI":"10.1093\/annonc\/mdt350"},{"key":"403_CR40","doi-asserted-by":"publisher","unstructured":"Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. https:\/\/doi.org\/10.1146\/annurev-med-070909-182917 (2011).","DOI":"10.1146\/annurev-med-070909-182917"},{"key":"403_CR41","first-page":"1497","volume":"5","author":"D Tong","year":"1999","unstructured":"Tong, D. et al. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer. Clin. Cancer Res. 5, 1497\u20131502 (1999).","journal-title":"Clin. Cancer Res."},{"key":"403_CR42","doi-asserted-by":"publisher","unstructured":"Gilam, A. et al. MicroRNA regulation of progesterone receptor in breast cancer. Oncotarget https:\/\/doi.org\/10.18632\/oncotarget.15657 (2017).","DOI":"10.18632\/oncotarget.15657"},{"key":"403_CR43","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1038\/s41467-020-19933-0","volume":"11","author":"YH Park","year":"2020","unstructured":"Park, Y. H. et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat. Commun. 11, 6175 (2020).","journal-title":"Nat. Commun."},{"key":"403_CR44","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.3389\/fimmu.2019.02802","volume":"10","author":"J P\u00e9rez-Pena","year":"2019","unstructured":"P\u00e9rez-Pena, J. et al. A Transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors. Front. Immunol. 10, 2802 (2019).","journal-title":"Front. Immunol"},{"key":"403_CR45","doi-asserted-by":"publisher","first-page":"e002198","DOI":"10.1136\/jitc-2020-002198","volume":"9","author":"M Graeser","year":"2021","unstructured":"Graeser, M. et al. Original research: Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. J. Immunother. Cancer 9, e002198 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"403_CR46","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396, 1090\u20131100 (2020).","journal-title":"Lancet"},{"key":"403_CR47","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"403_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda, R. et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 6, 1 (2020).","journal-title":"JAMA Oncol."},{"key":"403_CR49","doi-asserted-by":"publisher","unstructured":"den Brok, W. D. et al. Homologous recombination deficiency in breast cancer: a clinical review. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.16.00031 (2017).","DOI":"10.1200\/PO.16.00031"},{"key":"403_CR50","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tranon.2019.10.010","volume":"13","author":"B Pellegrino","year":"2020","unstructured":"Pellegrino, B. et al. Homologous recombination repair deficiency and the immune response in breast cancer: a literature review. Transl. Oncol. 13, 410 (2020).","journal-title":"Transl. Oncol."},{"key":"403_CR51","doi-asserted-by":"publisher","unstructured":"Szekely, B. et al. Immunological differences between primary and metastatic breast cancer. Ann. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdy399 (2018).","DOI":"10.1093\/annonc\/mdy399"},{"key":"403_CR52","doi-asserted-by":"publisher","first-page":"103100","DOI":"10.1016\/j.ebiom.2020.103100","volume":"62","author":"A Alba-Bernal","year":"2020","unstructured":"Alba-Bernal, A. et al. Challenges and achievements of liquid biopsy technologies employed in early breast cancer. EBioMedicine 62, 103100 (2020).","journal-title":"EBioMedicine"},{"key":"403_CR53","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160\u20131167 (2009).","journal-title":"J. Clin. Oncol."},{"key":"403_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0129-6","volume":"8","author":"B Wallden","year":"2015","unstructured":"Wallden, B. et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med. Genomics 8, 54 (2015).","journal-title":"BMC Med. Genomics"},{"key":"403_CR55","doi-asserted-by":"publisher","first-page":"e24243","DOI":"10.1200\/JCO.2018.36.15_suppl.e24243","volume":"36","author":"HA Brauer","year":"2018","unstructured":"Brauer, H. A., Mashadi-Hossein, A., Buckingham, W., Danaher, P. & Ferree, S. Gene expression signature development to decode breast cancer heterogeneity. J. Clin. Oncol. 36, e24243 (2018).","journal-title":"J. Clin. Oncol"},{"key":"403_CR56","doi-asserted-by":"publisher","unstructured":"Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under dependency. Ann. Stat. https:\/\/doi.org\/10.1214\/aos\/1013699998 (2001).","DOI":"10.1214\/aos\/1013699998"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00403-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:24:05Z","timestamp":1669299845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00403-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["403"],"URL":"https:\/\/doi.org\/10.1038\/s41523-022-00403-3","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"assertion":[{"value":"2 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. declares no conflicts of interest. S.K. reports consulting fees from F. Hoffmann-La Roche Ltd., Genomic Health, Novartis, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Somatex, MSD, Pfizer, Puma Biotechnology, PFM Medical, Lilly and SonoScape; leadership roles with Westdeutsche Studiengruppe and Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie; research grant\/funding from Somatex and Roche; travel expenses from F. Hoffmann-La Roche Ltd., Daiichi-Sankyo and SonoScape; and partial non-profit ownership of Westdeutsche Studiengruppe. N.H. reports fees for lectures and\/or consulting from AstraZeneca, Daiichi Sankyo, MSD, Lilly, Novartis, Pfizer, Roche, and Seattle Genetics; partial non-profit ownership of West German Study Group (WSG). P.S. reports advisory\/consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Puma, and Roche; grant\/funding to the institution from Astellas, AstraZeneca, Genentech, Novartis, Oncogenex and Roche; and a spouse who is an employee of Roche. J.C. reports advisory role\/consultancy for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, and Boehringer Ingelheim; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme, and Daiichi Sankyo; research funding to the institution from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH\/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma C, and Queen Mary University of London; stock, patents and intellectual property from MedSIR; and travel, accommodation, expenses from Roche, Novartis, Eisai, Pfizer, and Daiichi Sankyo. C.S. reports travel expenses from Teva. O.C. reports travel expenses from Pfizer. H.H. reports travel expenses from Teva and Pfizer. B.A. reports personal fees and non-financial support from Roche, personal fees from Amgen, personal fees from AstraZeneca, personal fees and non-financial support from Tesaro\/GSK, personal fees from Clovis, personal fees from Celgene, non-financial support from PharmaMar, personal fees and non-financial support from MSD, personal fees from Novartis, outside the submitted work. M.H.D. reports personal fees from Boehringer Ingelheim, Merck, Novartis, EUSA Pharma, AbbVie, Janssen, Biogen, Menarini and Norgine (outside the submitted work). S.S. reports professional fees from Sanofi, Abbvie, Bayer, Cantargia, Celgene, Ferring, Nestle, Servier, Tiburio, and Zentiva on unrelated freelance projects. E.T. has declared no conflicts of interest. I.T. has declared no conflicts of interest. D.G. has declared no conflicts of interest. O.G. reports minority non-profit ownership of WSG Study Group; honoraria from Genomic Health, Roche, Celgene, Pfizer, Novartis, NanoString Technologies, and AstraZeneca; consulting\/advisory board roles at Amgen, Roche, Daiichi Sankyo, Genomic Health, Merck Sharp & Dohme, Lilly, Novartis, Astra Zeneca, and Eisai; and travel\/accommodation\/expenses from Roche, Celgene, Daiichi Sankyo. M.R. reports honoraria (self) and advisory\/consultancy fees from Roche, Novartis, Merck Sharp & Dohme, AstraZeneca, Seagen, Somatex and Lilly; and travel expenses from Novartis and Pfizer and Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}